Event Information

Time：March 26, 2015 (Thursday)
Place：TRPMA Conference Room

TRPMA invited Dr. Ming-Chu Hsu, Chairman of TaiGen Biotechnology, to give a talk on the selection of new drug development projects, follow-up R&D and global strategies based on the story behind the success of Taigexyn®. Taigexyn® is the first licensed new chemical entity (NCE) developed in Taiwan. Its success was down to careful considerations of market demand, high success rate of the R&D of antibiotics and an opportunity for products with low resistance rate. The US authority introduced the GAIN Act in 2012 to encourage the development of antibiotics. Taigexyn® has already obtained the QIDP designation which gives 10- year market exclusivity to products once their marketing authorization is approved. TaiGen is now working with ZheJiang Medicine to explore the market in China.